Latigo Biotherapeutics

US · LTGO #3230 by market cap Listed 2026

15.52 -0.74 -4.55%

Live - 5344 symbols - heartbeat 125s ago · 2026-10-07 19:54

After-hours 15.89 +2.38%

Market cap: 1.03B
P/E (TTM): -9.26
P/B: -3.73
EPS: -1.82
Div yield: 0.00%
52W pos: 2%

Reader sentiment Are you bullish or bearish on LTGO?

Anonymous reader poll. Unscientific, not investment advice.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

CEO: Mr. Nima Farzan
Employees: 59
Fiscal year end: 12-31
Website: latigobio.com

Company profile

Exchange: US
Symbol: LTGO
Market-cap rank: #3230
Listing date: 2026-08-07
Market cap: 1.03B
Float cap: 248.32M
Shares out: 66.30M
Float shares: 16.00M

Sectors & themes

Biotechnology IPOs

Browse all sectors & themes

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.